{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:08:08Z","timestamp":1761919688067,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":3542,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/labinvest.2013.43","type":"journal-article","created":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T09:59:53Z","timestamp":1362391193000},"page":"502-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503"],"prefix":"10.1016","volume":"93","author":[{"given":"Ning-Ning","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuka","family":"Ohkouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Hashikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Kajimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Isozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Toh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshirou","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/labinvest.2013.43_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1038\/labinvest.2013.43_bib2","first-page":"1259","article-title":"Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal","volume":"152","author":"Kindblom","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1038\/labinvest.2013.43_bib3","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/j.1460-2075.1987.tb02655.x","article-title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand","volume":"6","author":"Yarden","year":"1987","journal-title":"EMBO J"},{"key":"10.1038\/labinvest.2013.43_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/320415a0","article-title":"A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family","volume":"320","author":"Besmer","year":"1986","journal-title":"Nature"},{"key":"10.1038\/labinvest.2013.43_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/j.1460-2075.1988.tb02907.x","article-title":"Primary structure of c-kit: relationship with the CSF-1\/PDGF receptor kinase family\u2013oncogenic activation of v-kit involves deletion of extracellular domain and C terminus","volume":"7","author":"Qiu","year":"1988","journal-title":"EMBO J"},{"key":"10.1038\/labinvest.2013.43_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0092-8674(90)90297-R","article-title":"Identification of a ligand for the c-kit proto-oncogene","volume":"63","author":"Williams","year":"1990","journal-title":"Cell"},{"key":"10.1038\/labinvest.2013.43_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0065-2660(08)60549-0","article-title":"Hereditary anemias of the mouse: a review for geneticists","volume":"20","author":"Russell","year":"1979","journal-title":"Adv Genet"},{"key":"10.1038\/labinvest.2013.43_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V53.3.492.492","article-title":"Decreased production of mast cells in Sl\/Sld anemic mice","volume":"53","author":"Kitamura","year":"1979","journal-title":"Blood"},{"key":"10.1038\/labinvest.2013.43_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/373347a0","article-title":"W\/kit gene required for intestinal cells of cajal and for intestinal pacemaker activity","volume":"373","author":"Huizinga","year":"1995","journal-title":"Nature"},{"key":"10.1038\/labinvest.2013.43_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0016-5085(95)90333-X","article-title":"Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws\/Ws mutant rats","volume":"109","author":"Isozaki","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1038\/labinvest.2013.43_bib11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"10.1038\/labinvest.2013.43_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0016-5085(03)01046-1","article-title":"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors","volume":"125","author":"Hirota","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1038\/labinvest.2013.43_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","article-title":"KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors","volume":"156","author":"Lux","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1038\/labinvest.2013.43_bib14","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.2013.43_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E","article-title":"Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours","volume":"193","author":"Hirota","year":"2001","journal-title":"J Pathol"},{"key":"10.1038\/labinvest.2013.43_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1440-1746.2003.02911.x","article-title":"C-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors","volume":"18","author":"Kinoshita","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1038\/labinvest.2013.43_bib17","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1038\/labinvest.2013.43_bib18","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/labinvest.2013.43_bib19","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/ijc.21607","article-title":"Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumor","volume":"118","author":"Hostein","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1038\/labinvest.2013.43_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pbc.20377","article-title":"Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)","volume":"45","author":"Price","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1038\/labinvest.2013.43_bib21","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1038\/labinvest.2013.43_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/labinvest.2013.43_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/labinvest.2013.43_bib24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study","volume":"358","author":"van Oosterom","year":"2001","journal-title":"Lancet"},{"key":"10.1038\/labinvest.2013.43_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/labinvest.2013.43_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.11025","article-title":"Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors","volume":"105","author":"Chen","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1038\/labinvest.2013.43_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.20305","article-title":"Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and AKT and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha","volume":"111","author":"Ohashi","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1038\/labinvest.2013.43_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","article-title":"Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants","volume":"128","author":"Debiec-Rychter","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1038\/labinvest.2013.43_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/sj.bjc.6601819","article-title":"Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation","volume":"90","author":"Wakai","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1038\/labinvest.2013.43_bib30","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-04-0085","article-title":"A missense mutation in KIT kinase domain I correlates with imatinib resistance in gastrointestinal stromal tumors","volume":"64","author":"Chen","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/labinvest.2013.43_bib31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2004.02.021","article-title":"A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient","volume":"127","author":"Tamborini","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1038\/labinvest.2013.43_bib32","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1038\/labinvest.2013.43_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","article-title":"AMN107: Tightening the grip of imatinib","volume":"7","author":"O'Hare","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1038\/labinvest.2013.43_bib34","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/labinvest.2013.43_bib35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/ehm.10.61","article-title":"Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study","volume":"3","author":"Giles","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1038\/labinvest.2013.43_bib36","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1038\/labinvest.2013.43_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Hematol"},{"key":"10.1038\/labinvest.2013.43_bib38","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ejca.2009.05.010","article-title":"Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and\/or metastatic solid cancers","volume":"45","author":"Soria","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1038\/labinvest.2013.43_bib39","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients","volume":"28","author":"Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/labinvest201343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/labinvest201343","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722009412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722009412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/labinvest201343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:33:05Z","timestamp":1758396785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722009412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0023683722009412"],"URL":"https:\/\/doi.org\/10.1038\/labinvest.2013.43","relation":{},"ISSN":["0023-6837"],"issn-type":[{"type":"print","value":"0023-6837"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/labinvest.2013.43","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}